When Nameplate Becomes an Opinion
Kronos told the SEC it moved its own definition of a normal production rate. Lanxess told analysts it is running below 70% and taking nothing out. Plus STERIS trades two chemistry plants for one, a Rhine force majeure that never existed, and a Kaub recovery that lasted two days.
A plant can leave the market without anybody shutting it.
Kronos told the SEC on Wednesday that it had moved its own definition of a normal production rate. Lanxess told analysts on Friday that it is running below 70% and intends to take nothing out.
Same week, same problem, opposite paperwork. Neither one produced a closure announcement, and both of them changed what the industry can actually make.
Kronos moved the range, not the plant
The line is in the MD&A of the 10-Q Kronos filed Wednesday, and it is worth reading twice:
"As a result, we adjusted our normal production capacity range in 2026 to reflect our production capabilities under this new cost structure."
The new cost structure is the fourth-quarter 2025 programme of workforce reductions and other measures, taken so the company could "enable more efficient operation of our facilities at lower production rates for extended periods."
The rest of this brief is for subscribers.
The capacity math, the trade-flow read, and what it means for the products you buy.
$100 a month, or $800 a year.
Already a subscriber? Sign in